Commons, Marty

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Efficacy and Safety of FTY720 Versus Mycophenolate Mofetil (MMF, Roche Brand) in de Novo Adult Renal Transplant Recipients

Phase 3
Completed
Conditions
Renal Transplantation
First Posted Date
2005-10-17
Last Posted Date
2017-02-23
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
684
Registration Number
NCT00239863

Long Term Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

Phase 3
Completed
Conditions
Renal Transplantation
First Posted Date
2005-10-17
Last Posted Date
2011-11-02
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
684
Registration Number
NCT00239811

Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

Phase 3
Completed
Conditions
Renal Transplantation
First Posted Date
2005-10-17
Last Posted Date
2011-11-02
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
140
Registration Number
NCT00239876

Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

Phase 2
Completed
Conditions
Renal Transplantation
First Posted Date
2005-10-17
Last Posted Date
2011-11-02
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
396
Registration Number
NCT00239902

Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation

First Posted Date
2005-10-14
Last Posted Date
2017-03-30
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
134
Registration Number
NCT00239005
Locations
🇬🇧

Novartis Investigative Site, Nottingham, United Kingdom

Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen in de Novo Renal Transplant Recipients.

Phase 3
Completed
Conditions
Kidney de Novo Transplant
First Posted Date
2005-10-14
Last Posted Date
2011-11-02
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
144
Registration Number
NCT00238992

An Open Label Study to Evaluate the Tolerability and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion (CsA-ME) in Maintenance Renal Transplant Recipients

Phase 3
Completed
Conditions
Kidney Transplant Recipients
First Posted Date
2005-10-14
Last Posted Date
2011-11-02
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
40
Registration Number
NCT00239044

A Study to Investigate the Tolerability and Safety of Converting Stable Renal Transplant Recipients Who Receive Tacrolimus With or Without Corticosteroids From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS)

Phase 4
Completed
Conditions
Renal Transplantation
First Posted Date
2005-10-14
Last Posted Date
2011-11-02
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
50
Registration Number
NCT00238979

A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion

Phase 4
Completed
Conditions
Diabetes Mellitus, Type 2
First Posted Date
2005-10-13
Last Posted Date
2012-04-27
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
24
Registration Number
NCT00238472

Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Heart Transplant Recipients

First Posted Date
2005-10-13
Last Posted Date
2017-02-24
Lead Sponsor
Novartis Pharmaceuticals
Registration Number
NCT00238446
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy